Loss of heterozygosity at 15q21.3 correlates with occurrence of metastases in head and neck cancer

Modern Pathology

Volumn 19, Issue 11, 2006, Pages 1462-1469

  Poetsch, Micaela ^a   Kleist, Britta ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Chromosome 15q; Head and neck carcinoma; Loss of heterozygosity

Indexed keywords

ALLELIC IMBALANCE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER RISK; CHROMOSOME 15Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MAPPING; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MICROSATELLITE MARKER; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 15; HEAD AND NECK NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; LYMPH NODES; LYMPHATIC METASTASIS; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 33750330089     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800666     Document Type: Article

References (47)

1. Parkin DM, Läärä E, Muir CS. Estimates of the world wide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-197.
2. Blons H, Laurent-Puig P. TP53 and head and neck neoplasms. Hum Mut 2003;21:252-257.
3. Hong WK, Lippmann SM, Itri LM. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
4. Beder LB, Gunduz M, Ouchida M, et al. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 2003;83:99-105.
5. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994;21:281-288.
6. Franceschi S, Munoz N, Bosch XF, et al. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996;5:567-575.
7. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139-146.
8. Bockmuhl U, Petersen S, Schmidt S, et al. Patterns of chromosomal alterations in metastasizing and non-metastasizing primary head and neck carcinomas. Cancer Res 1997;57:5213-5216.
9. Feenstra M, Veltkamp M, von Kulk J, et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999;54:235-245.
10. Squire JA, Bavani J, Luk C, et al. Molecular cytogenetic analysis of head and neck squamous cell carcinoma: by comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck 2002;24:874-887.
11. Brieger J, Jacob R, Riazimand HS, et al. Chromosomal aberrations in premalignant and malignant squamous epithelium. Cancer Genet Cytogenet 2003;144:148-155.
12. Hannen EJM, Macville MVE, Wienk SM, et al. Different chromosomal imbalances in metastasized and nonmetastasized tongue carcinomas identified by comparative genomic hybridization. Oral Oncol 2004;40:364-371.
13. Koene GJPA, Arts-Hilkes YHA, van der Ven KJW, et al. High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of β2-microglobulin LOH analysis. Tissue Antigens 2004;84:452-461.
14. Hu N, Roth MJ, Polymeropolous M, et al. Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous-cell carcinoma in a high-risk Chinese population. Genes Chromosomes Cancer 2000;27:217-228.
15. Yen CC, Chen YJ, Lu KH, et al. Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction. Int J Oncol 2003;23:871-881.
16. Anneroth G, Batsakis J, Kyba N. Review of the literature and recommended system of malignancy grading in oral squamous cell carcinoma. Scand J Dent Res 1987;95:229-249.
17. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors, 6th edn. Wiley-Liss: New York, 2002.
18. Poetsch M, Dittberner T, Woenckhaus C. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogenet 2001;125:21-26.
19. Poetsch M, Zimmermann A, Wolf E, et al. Loss of heterozygosity occurs predominantly, but not exclusively in the epithelial compartment of pleomorphic adenoma. Neoplasia 2005;7:688-695.
20. Wick W, Petersen I, Schmutzler RK, et al. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 1996;12:973-978.
21. Natrajan R, Louhelainen J, Williams S, et al. High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder. Cancer Res 2003;63:7657-7662.
22. De Rienzo A, Balsara BR, Apostolou S, et al. Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene 2001;20:6245-6249.
23. Kee HJ, Shin JH, Chang J, et al. Identification of tumor suppressor loci on the long arm of chromosome 15 in primary small cell lung cancer. Yonsei Med J 2003;44:65-74.
24. Riehm K, Klein A, Münch M, et al. Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. Int J Cancer 2003;106:74-77.
25. Tahara H, Smith AP, Gas RD, et al. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 1996;56:599-605.
26. Van Dyke DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994;3:192-206.
27. Jin Y, Mertens F, Jin C, et al. Nonrandom chromosome abnormalities in short-term cultured primary squamous cell carcinomas of the head and neck. Cancer Res 1995;55:3204-3210.
28. Tremmel SC, Götte K, Popp S, et al. Intratumoral genomic heterogeneity in advanced head and neck cancer detected by comparative genomic hybridization. Cancer Genet Cytogenet 2003;144:165-174.
29. Wreesmann VB, Wang D, Goberdhan A, et al. Genetic abnormalities associated with nodal metastasis in head and neck cancer. Head Neck 2004;26:10-15.
30. Gotte K, Tremmel SC, Popp S, et al. Intratumoral genomic heterogenetity in advanced head and neck cancer detected by comparative genomic hybridization. Adv Otorhinolaryngol 2005;62:38-48.
31. Jin C, Jin Y, Wennerberg J, et al. Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet 2002;132:85-96.
32. Losi L, Baisse B, Bouzourene H, et al. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005;26:916-922.
33. Jones TD, Eble JN, Wang M, et al. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer 2005;104:1195-1203.
34. Fukunari H, Iwama T, Sugihara K, et al. Intratumoral heterogenetity of genetic changes in primary colorectal carcinomas with metastasis. Surg Today 2003;33:408-413.
35. Jones TD, Carr MD, Eble JN, et al. Clonal origin of lymph node metastases in bladder carcinoma. Cancer 2005;104:1901-1910.
36. Jordanova ES, Corver WE, Vonk MJ, et al. Flow cytometric sorting of paraffin-embedded tumor tissues considerably improves molecular genetic analysis. Am J Clin Pathol 2003;120:327-334.
37. Liu J, Zabarovska VI, Braga E, et al. Loss of heterozygosity in tumor cells requires re-evaluation: the data are biased by the size-dependent differential sensitivity of allele detection. FEBS Lett 1999;462:121-128.
38. Edwards MC, Liegeois N, Horecka J, et al. Human CPR (cell cycle progression restoration) genes impart a Far-phenotype on yeast cells. Genetics 1997;147:1063-1076.
39. Samadani U, Costa RH. The transcriptional activator hepatocyte nuclear factor 6 regulates liver gene expression. Mol Cell Biol 1996;16:6273-6284.
40. Kramps T, Peter O, Brunner E, et al. Wnt/Wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002;109:47-60.
41. Zhang H, Holzgreve W, De Geyter C. Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway. Hum Mol Genet 2001;10:2329-2339.
42. Chau BN, Cheng EH, Kerr DA, et al. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 2000;6:31-40.
43. Casaubon LK, Melanson M, Lopes-Cendes I, et al. The gene responsible for a severe form of peripheral neuropathy and agenesis of the corpus callosum maps to chromosome 15q. Am J Hum Genet 1996;58:28-34.
44. Glenn CC, Driscoll DJ, Yang TP, et al. Genomic imprinting: potential function and mechanisms revealed by the Prader-Wili and Angelman syndromes. Mol Hum Reprod 1997;3:321-332.
45. Windpassinger C, Petek E, Wagner K, et al. Molecular characterization of a unique de novo 15q deletion associated with Prader-Willi syndrome and central visual impairment. Clin Genet 2003;63:297-302.
46. Smith JS, Tachibani I, Pohl U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 2000;64:44-50.
47. Yang P, Kollmeyer TM, Buckner K, et al. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer 2005;103:2363-2372.